🏢 官网IRCOCODoubao · 实盘不做把握 6/10不做原因:风险收益比不佳
北京时间·🕒 发布 19:00:49(美东 07:00)·⟳ 抓取 19:03:41回填·⚡ 决策 10-22 19:09:25 +8m36s·5.0 天前
Vita Coco Q3营收+34%、上调全年指引,但Q4毛利率指引骤降至约33%,盘前冲高回落翻绿
名义beat并上调全年指引属正面,但公司同时给出Q4毛利率仅约33%的明确利润率警告(成本上升、2027前无提价),盘前真实价格反应为冲高(+2.4%)后回落翻绿(-2.36%),且财报前5日已放量抢跑+8.4%、估值PE(TTM)53;做多被利润率警告与已price-in压制,做空又面对全年EBITDA指引大幅上修的强基本面,不满足做空红线,风险收益不对称,故不做。
📄 原文COCO↗ 原文
The Vita Coco Company Reports Third Quarter 2026 Financial Results and Raises Full Year Guidance
PDF Version Net Sales Increased 34%, Driven by Vita Coco Coconut Water Growth of 15%; Organic Net Sales Growth 1 of 18%…
不做 The Vita Coco Company(COCO.US)
beat+raise被Q4毛利率约33%的明确警告对冲,盘前冲高(+2.4%)回落已翻绿(-2.36%),且财报前5日放量抢跑+8.4%、PE(TTM)53,做多edge不足;做空面对全年EBITDA指引大幅上修的强基本面、不符合做空红线。多空风险收益均不对称,不做;待电话会与开盘承接确认利润率与提价路径后再评估。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
COCO Q3营收+34%、有机+18%并上调全年营收/EBITDA指引,但Q4毛利率指引骤降至约33%且提价要等2027年初;盘前冲高回落已翻绿、财报前5日抢跑+8.4%,利好被利润率警告与提前定价对冲,多空皆无正edge。
🔎 新鲜度:最早出现 2026-10-22 · 扩散 low · price-in 风险 high ↗
消息传播链
- 公司一手发布Q3财报并上调全年指引,同时预警Q4毛利率约33%;电话会安排在美东8:30市场反应:盘前(07:07)价62.0美元,较前收63.5跌2.36%,区间60-65冲高(曾+2.4%)后翻绿,盘前量仅1355股
关键理由
- 全年Adj EBITDA指引中值由157.5M大幅上修至172.5M(约+10%),且有机增长18%、无负债,基本面方向偏多
- 但Q4毛利率约33%的明确预警+财报前抢跑+盘前翻绿,说明市场把本季beat视为兑现而非新增edge
主要风险
- Q4毛利率约33%为全年低点,海运/运费上行与Copra自有品牌摊薄短期压缩利润,若电话会确认成本压力延续至2027将进一步压制估值
- 盘前成交量极低(约1355股)、买卖价差极宽(61.63/66.0),62美元的盘前价代表性弱,开盘可能大幅双向跳空
反向证据
- 做多前查反向 · 来源 filing · 日期 2026-10-22 · 影响 weakens
公司在一手稿明确Q4毛利率约33%(成本上升、2027年初前无提价),且全年毛利率受Copra自有品牌mix拖累,直接削弱短期盈利斜率
检索:COCO Q4 gross margin guidance 33% tariff freight cost 2027 pricing 原文 ↗ - 做空前查反向 · 来源 filing · 日期 2026-10-22 · 影响 invalidates
全年营收指引上调至810-820M、Adj EBITDA大幅上调至170-175M,有机增长18%、无负债、持续回购,强基本面不支持以财报为据做空
检索:COCO raised FY2026 net sales Adjusted EBITDA guidance 810-820 170-175 organic growth 18% 原文 ↗
先例如何影响了这次决策
对本次决策的影响:先例缺失叠加盘前已负反应与抢跑,支持不做而非强行给方向性交易
方向:无可供event_study锚定的高相似、首发可溯源同市场先例面板,未据此校准
涨幅量级:不足:未取得干净对齐样本,不据此设定tp/sl
形态:仅以本次盘前真实价格行为(冲高回落翻绿)作为见光死迹象,不外推为统计规律
工具执行结果 · 成功 4 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 7,112 ms
{"result": "search_processed_events:agent query=`vita coco coco q3 2026 earnings results guidance raised | vita coco third quarter 2026 net sales ebitda outlook copra`;结构化索引覆盖完整 72 小时;旧记录兼容扫描近 72.0/72 小时、26126 条本臂决策(完整),返回 0 条候选。未命中只表示这些 agent query 表达式没有召回候选,不能据此证明消息首发或不是重复;按当前事件继续正常研判。"} - stock_quote 成功 stock_tools HTTP · 7,102 ms
{ - fetch_decision_experience 成功 stock_tools_inprocess · 1 ms
{ - web_search 成功 doubao_search · 1,515 ms
豆包搜索结果(原始查询:Vita Coco COCO Q3 2026 earnings beat estimates analyst reaction premarket October 22 2026;API SearchType:web)
原文全文
展开原文 · 24,961 字
PDF Version
Net Sales Increased 34%, Driven by Vita Coco Coconut Water Growth of 15%; Organic Net Sales Growth
1
of 18%
Net Income Increased $11 million to $35 million and Non-GAAP Adjusted EBITDA² Increased $21 million to $53 million
Raises Fiscal Year 2026 Guidance for Net Sales to Between
$810
Million and
$820
Million and Non-GAAP Adjusted EBITDA²
to between
$170
million and
$175
million
NEW YORK, Oct. 22, 2026 (GLOBE NEWSWIRE) -- The Vita Coco Company, Inc. (NASDAQ:COCO) (“Vita Coco” or “the Company”), a leading high-growth platform of better-for-you beverage brands, today announced financial results for the third quarter ended September 30, 2026.
Third Quarter and Year-to-Date 2026 Highlights Compared to Prior Year Period
Net sales were $244 million, an increase of $62 million, or 34%, in the third quarter
,
and $640 million year-to-date, an increase of $158 million, or 33%.
Organic net sales growth
1
was 18% in the third quarter and 27% year-to-date.
Vita Coco
Coconut Water net sales grew 15% in the third quarter and 24% year-to-date.
Private Label net sales grew 152% in the third quarter and 85% year-to-date, with the third quarter benefiting from the contribution of Copra, a leading producer of super premium Thai Nam Hom coconut water that was acquired in July 2026.
Gross profit was $93 million in the third quarter, an increase of $24 million, and $270 million year-to-date, an increase of $92 million.
Gross margin was 38% of net sales in the third quarter consistent with prior year, and was 42% of net sales year-to-date compared to 37%, with tariff refunds delivering a 240 basis point benefit to gross margin year-to-date.
Net income was $35 million in the third quarter, compared to $24 million, an increase of $11 million, and $115 million year-to-date, compared to $66 million, an increase of $49 million.
Net income per diluted share was $0.58 in the third quarter, compared to $0.40, and $1.89 per diluted share year-to-date, compared to $1.10.
Non-GAAP Adjusted EBITDA² was $53 million in the third quarter, compared to $32 million, an increase of $21 million. Non-GAAP Adjusted EBITDA
2
was $159 million year-to-date, compared to $84 million, an increase of $75 million.
Michael Kirban, the Company's Co-Founder and Executive Chairman, stated, “The growth of the coconut water category maintained through the fall, and remains one of the fastest growing beverage categories in our major markets. I am particularly pleased by the strong growth in Europe as we develop the category in key markets, and the continued growth in America, driven by increases in both household penetration and in average consumption per household. This quarter, we were pleased to welcome the Copra team to our family and to start executing our joint plans, which we believe will allow us to compete successfully in the super premium segment. With the investments we are making in our supply chain, and our strong brand performance, I am confident in our plans to maintain our growth into 2027, and our category leadership well into the future.”
Martin Roper, the Company’s Chief Executive Officer, said, “Our strong third quarter net sales growth was driven by robust branded retail growth in all our major markets, and by strong growth in private label shipments, reflecting healthy category growth and the addition of Copra's super premium products. Excluding the impact of Copra, the underlying 18% organic net sales growth of our business remained very strong, exceeding our expectations. Consumer demand is very healthy, and we are therefore raising our full year Net Sales and Adjusted EBITDA guidance.”
Third Quarter 2026 Consolidated Results
Net sales increased $62 million, or 34%, to $244 million for the third quarter ended September 30, 2026, compared to $182 million in the prior year period. The increase in net sales was driven by case equivalent (“CE”) volume gains of 16% for
Vita Coco
Coconut Water and 77% for Private Label. Organic net sales growth
1
, which is net sales growth excluding the impact of Copra, was 18% for the quarter. Copra net sales primarily impacted Private Label, with Copra branded coconut water and commodity net sales recognized in Other.
Gross profit increased to $93 million, from $69 million in the prior year period driven by higher sales volume, the addition of Copra, and minimal tariffs compared to the prior year period, partially offset by higher domestic logistics costs. Gross margin was 38%, in line with the prior year period, benefitting from minimal tariffs compared to the prior year period, offset by higher domestic logistics costs, and the dilutive impact of Copra.
Selling, general and administrative (“SG&A”) expenses were $47 million, compared to $41 million in the prior year period. The increase was primarily driven by costs related to the acquisition of Copra, amortization expense associated with intangible assets acquired in the Copra acquisition, higher people-related costs reflecting increased headcount and stock-based compensation, as well as higher sales related expenses.
Net income was $35 million, or $0.58 per diluted share, compared to net income of $24 million, or $0.40 per diluted share, in the prior year period. Net income benefited from higher gross profit, partially offset by higher SG&A spending and increased income tax expense.
Non-GAAP Adjusted EBITDA
2
was $53 million, compared to $32 million in the prior year due to the increased gross profit partially offset by higher SG&A expenses.
Balance Sheet
As of September 30, 2026, the Company's financial position remained strong with no debt and $152 million in cash and cash equivalents. Cash decreased $45 million from the beginning of the year, and $127 million from end of the second quarter due to net cash used for the acquisition of Copra of $139 million. Our inventory was $111 million, flat to December 31, 2025, with the inclusion of Copra inventory offsetting the inventory draw down from strong year-to-date shipments. Accounts receivable increased to $129 million from $82 million as of prior year end due to strong quarterly sales and the inclusion of Copra.
As of September 30, 2026, the Company had repurchased approximately $86 million of its common stock under its share repurchase program and had $19 million remaining under the existing authorization. During the nine months ended September 30, 2026, the Company repurchased $62 million of its common stock. As of October 22, 2026, the Company has repurchased $94 million of its common stock, and had $11 million remaining of the $105 million authorized amount under the repurchase program.
Fiscal Year 2026 Full Year Outlook³
The Company is increasing its full year 2026 guidance, as follows:
Net sales expected to be between $810 million and $820 million, driven by low 20s percent growth of Vita Coco Coconut Water, strong Private Label trends and the addition of Copra. (Prior guidance was between $790 million and $805 million, which included the benefit of Copra).
Gross margin expected to be approximately 40% with benefit relative to prior year from lower tariffs, tariff refunds, and higher pricing partially offset by increased ocean freight, product and other transportation costs, alongside adverse product mix, primarily due to the impact of Copra's private label business and strong private label trends. (No change from prior guidance). Fourth quarter gross margin expected to be approximately 33% due to increases in cost of goods and no offsetting price actions expected until early 2027.
Expect to deliver SG&A leverage of approximately 1.5 percentage points of net sales vs. 2025. (Prior guidance was one percentage point).
Adjusted EBITDA
²
expected to be in the range of $170 million to $175 million. (Prior guidance was between $154 million and $161 million).
Uncertainty and instability in the current operating environment, geopolitical landscape, and global economies, including the military conflict in Iran and related impacts, changes in tariff rates, natural disasters, associated potential competitive pricing actions, and our own price elasticity could affect this outlook and our future results.
Footnotes
(1)
Organic net sales growth is a supplemental measure of net sales performance that excludes the impact of net sales attributable to the Copra acquisition as set forth in the U.S. GAAP to non-GAAP reconciliation table below.
(2)
Adjusted EBITDA represents earnings before interest, taxes, depreciation, and amortization as adjusted for certain items as set forth in the reconciliation table of U.S. GAAP to non-GAAP information and is a measure calculated and presented on the basis of methodologies other than in accordance with GAAP. Please refer to the Non-GAAP Financial Measures herein for further discussion and reconciliation of this measure to GAAP measures.
(3)
GAAP Net income 2026 outlook is not provided due to the inherent difficulty in quantifying certain amounts due to a variety of factors including the unpredictability in the movement in foreign currency rates, as well as future charges or reversals outside of the normal course of business.
Conference Call and Webcast Details
To participate in the live earnings call and question and answer session, please register at
https://register-conf.media-server.com/register/BIb7dfca7ed24e41c7a1cd98a3f2cfb4e0
and dial-in information will be provided directly to you. The live audio webcast will be accessible in the “Events” section of the Company’s Investor Relations website at
https://investors.thevitacococompany.com
. An archived replay of the webcast will be available shortly after the live event has concluded.
About The Vita Coco Company
The Vita Coco Company is a family of brands on a mission to reimagine what’s possible when brands deliver healthy, nutritious
,
and great tasting products that are better for consumers and better for the world. This includes its flagship coconut water brand Vita Coco, and Copra, a super-premium brand that specializes in Thai Nam Hom coconut water. The Company was co-founded in 2004 by Michael Kirban and Ira Liran and is a public benefit corporation and Certified B Corporation. Vita Coco, the principal brand within the Company’s portfolio, is the leading coconut water brand in the U.S. With electrolytes and nutrients, coconut water has become a top beverage choice among consumers after a workout, in smoothies, as a cocktail mixer, after a night out and more.
Contacts
Investor Relations:
ICR, Inc.
investors@thevitacococompany.com
Non-GAAP Financial Measures
In addition to disclosing results determined in accordance with U.S. GAAP, the Company also discloses certain non-GAAP results of operations, including, but not limited to, Adjusted EBITDA, and organic net sales growth, which include certain adjustments or exclude certain charges and gains that are described in the reconciliation table of U.S. GAAP to non-GAAP information provided at the end of this release. These non-GAAP measures are a key metric used by management and our board of directors to assess our financial performance across reporting periods on a consistent basis by excluding items that we do not believe are indicative of our core operating performance and because we believe it is useful for investors to see the measures that management uses to evaluate the Company. In addition, we believe the presentation of these measures is useful to investors for period-to-period comparisons of results as the items described below in the reconciliation tables do not reflect ongoing operating performance.
These measures are not in accordance with, or an alternative to, U.S. GAAP, and may be different from non-GAAP measures used by other companies. In addition, other companies, including companies in our industry, may calculate such measures differently, which reduces their usefulness as a comparative measure. Investors should not rely on any single financial measure when evaluating our business. This information should be considered as supplemental in nature and is not meant as a substitute for our operating results in accordance with U.S. GAAP. We recommend investors review the U.S. GAAP financial measures included in this earnings release. When viewed in conjunction with our U.S. GAAP results and the accompanying reconciliations, we believe these non-GAAP measures provide greater transparency and a more complete understanding of factors affecting our business than U.S. GAAP measures alone.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, but not limited to, statements regarding our future financial and operating performance, including our GAAP and non-GAAP guidance, our strategy, projected costs, tariffs, prospects, expectations, plans, objectives of management, supply chain predictions, customer and supplier relationships, expected impact of acquisitions, and expected net sales and category share growth.
The forward-looking statements in this release are only predictions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Forward-looking statements involve a number of risks, uncertainties or other factors beyond the Company’s control. These factors include, but are not limited to, those discussed under the caption “Risk Factors” in our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and our other filings with the U.S. Securities and Exchange Commission (“SEC”) as such factors may be updated from time to time and which are accessible on the SEC’s website at www.sec.gov and the Investor Relations page of our website at https://investors.thevitacococompany.com. Any forward-looking statements contained in this press release speak only as of the date hereof and accordingly undue reliance should not be placed on such statements. We disclaim any obligation or undertaking to update or revise any forward-looking statements contained in this press release, whether as a result of new information, future events or otherwise, other than to the extent required by applicable law.
Website Disclosure
We intend to use our websites, vitacoco.com and investors.thevitacococompany.com, as a means for disclosing material non-public information and for complying with the SEC's Regulation FD and other disclosure obligations.
THE VITA COCO COMPANY, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(Amounts in thousands, except share data)
September 30,
2026
December 31,
2025
Assets
Current assets:
Cash and cash equivalents
$
151,995
$
196,873
Accounts receivable, net of allowance of $3,282 at September 30, 2026, and $2,660 at December 31, 2025
128,724
81,514
Inventory
111,296
111,468
Supplier advances, current
339
693
Derivative assets
1,794
732
Prepaid expenses and other current assets
39,536
30,160
Total current assets
433,684
421,440
Property and equipment, net
24,441
9,298
Goodwill
110,175
7,791
Intangible assets, net
107,116
—
Supplier advances, long-term
1,593
1,860
Deferred tax assets, net
6,627
6,623
Right-of-use assets, net
10,337
11,592
Other assets
2,169
2,714
Total assets
$
696,142
$
461,318
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable
$
46,389
$
25,464
Accrued expenses and other current liabilities
126,632
89,461
Derivative liabilities
2,059
1,507
Total current liabilities
175,080
116,432
Deferred tax liability
24,875
160
Operating lease liability, long-term
12,119
13,087
Seller's earn-out
55,100
—
Other long-term liabilities
240
97
Total liabilities
$
267,414
$
129,776
Stockholders’ equity:
Common stock, $0.01 par value; 500,000,000 shares authorized; 65,396,253 and 64,186,549 shares issued at September 30, 2026 and December 31, 2025, respectively; 57,202,356 and 57,082,173 shares outstanding at September 30, 2026 and December 31, 2025, respectively.
654
642
Additional paid-in capital
231,578
185,400
Retained earnings
342,956
228,014
Accumulated other comprehensive gain (loss)
(1,050
)
486
Treasury stock, 8,193,897 shares at cost as of September 30, 2026, and 7,104,376 as of December 31, 2025.
(145,410
)
(83,000
)
Total stockholders’ equity
428,728
331,542
Total liabilities and stockholders’ equity
$
696,142
$
461,318
THE VITA COCO COMPANY, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Amounts in thousands, except for share and per share data)
Three Months Ended September 30,
Nine Months Ended September 30,
2026
2025
2026
2025
Net sales
$
243,825
$
182,313
$
639,744
$
481,993
Cost of goods sold
151,148
113,645
369,942
303,975
Gross profit
92,677
68,668
269,802
178,018
Operating expenses
Selling, general and administrative
47,226
40,745
127,629
105,680
Income from operations
45,451
27,923
142,173
72,338
Other income (expense)
Unrealized (loss) gain on derivative instruments
(2,083
)
2,391
511
6,275
Foreign currency loss
(887
)
(1,411
)
(2,432
)
(349
)
Interest income, net
1,231
1,776
5,252
4,794
Other (expense) income, net
(84
)
—
(77
)
155
Total other (expense) income
(1,823
)
2,756
3,254
10,875
Income before income taxes
43,628
30,679
145,427
83,213
Income tax expense
8,611
6,676
30,485
17,420
Net income
$
35,017
$
24,003
$
114,942
$
65,793
Net income attributable to The Vita Coco Company, Inc. per common share
Basic
$
0.61
$
0.42
$
2.01
$
1.16
Diluted
$
0.58
$
0.40
$
1.89
$
1.10
Weighted-average number of common shares outstanding
Basic
57,453,252
56,850,812
57,274,270
56,879,627
Diluted
60,831,632
59,878,602
60,786,462
59,832,067
THE VITA COCO COMPANY, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Amounts in thousands)
Nine Months Ended September 30,
2026
2025
Cash flows from operating activities:
Net income
$
114,942
$
65,793
Adjustments required to reconcile net income to cash flows from operating activities:
Depreciation and amortization
2,458
636
Amortization of debt issuance cost
14
11
Increase of provision for credit losses
187
1,300
Unrealized (gain) on derivative instruments
(511
)
(6,275
)
Stock-based compensation
11,338
8,123
Impairment loss on Runa assets
—
185
Noncash lease expense
1,242
1,052
Changes in operating assets and liabilities:
Accounts receivable
(42,801
)
(39,706
)
Inventory
33,259
(302
)
Prepaid expenses, net supplier advances, and other assets
(7,236
)
345
Accounts payable, accrued expenses, and other liabilities
39,050
19,907
Net cash provided by operating activities
151,942
51,069
Cash flows from investing activities:
Cash paid for property and equipment
(803
)
(4,921
)
Acquisition of Copra Inc., net of $8,340 cash acquired
(139,253
)
—
Net cash used in investing activities
(140,056
)
(4,921
)
Cash flows from financing activities:
Proceeds from exercise of stock awards
6,131
2,281
Cash paid on notes payable
(3
)
(8
)
Cash paid to acquire treasury stock
(62,410
)
(10,204
)
Net cash used in financing activities
(56,282
)
(7,931
)
Effects of exchange rate changes on cash and cash equivalents
(475
)
833
Net (decrease) increase in cash and cash equivalents
(44,871
)
39,050
Cash, cash equivalents and restricted cash at beginning of the period (1)
198,154
165,933
Cash, cash equivalents and restricted cash at end of the period (1)
$
153,283
204,983
1
Includes $1,281 and $1,264 of restricted cash as of December 31, 2025 and 2024, respectively. Includes $1,288 and $1,278 of restricted cash as of September 30, 2026 and 2025, respectively, reported in other current assets on the condensed consolidated balance sheet.
During the nine months ended September 30, 2026, the Company issued common stock with a fair value of $35,000 and recognized contingent consideration with a fair value of $55,100 in connection with the acquisition of Copra. These transactions are reflected as noncash investing and financing activities.
RECONCILIATION FROM GAAP NET INCOME TO NON-GAAP ADJUSTED EBITDA
Three Months Ended September 30,
Nine Months Ended September 30,
2026
2025
2026
2025
(in thousands)
(in thousands)
Net income
35,017
24,003
$
114,942
$
65,793
Depreciation and amortization
1,493
228
2,458
636
Interest income, net
(1,231
)
(1,776
)
(5,252
)
(4,794
)
Income tax expense
8,611
6,676
30,485
17,420
EBITDA
$
43,890
$
29,131
$
142,633
$
79,055
Stock-based compensation (a)
3,122
2,975
11,338
8,123
Unrealized loss (gain) on derivative instruments (b)
2,083
(2,391
)
(511
)
(6,275
)
Foreign currency loss (b)
887
1,411
2,432
349
Acquisition-related costs (c)
3,174
—
3,174
—
Other adjustments (d)
—
1,264
—
2,886
Adjusted EBITDA
$
53,156
$
32,390
$
159,066
$
84,138
(a)
Non-cash charges related to stock-based compensation, which vary from period to period depending on volume and vesting timing of awards and forfeitures. We adjusted for these charges to facilitate comparison from period to period.
(b)
Unrealized gains or losses on derivative instruments and foreign currency gains or losses are not considered in our evaluation of our ongoing performance.
(c)
Acquisition-related costs represent transaction, advisory, legal, accounting, valuation, and other professional fees incurred in connection with the acquisition of Copra.
(d)
The three and nine months ended September 30, 2025 included $0.6 million and $1.8 million, respectively, related to a one-time incentive program established in 2023 and measured based on full-year 2025 performance, and $0.4 million and $1.1 million, respectively, of overlapping rent expense associated with our new New York City office, and $0.2 million of impairment loss related to the sale of Runa. The three months ended September 30, 2025 also includes $0.1 million of provision for credit losses related to the partially recovered prepaid inventory from a supplier recorded in the first half of 2025 (refer to the Form 10-K and the Form 10-Q for the quarterly period ended June 30, 2025 for further details). The nine month period was partially offset by $0.1 million of partial recoveries of prepaid inventory from a supplier (refer to the Form 10-K for further details) and a $0.2 million gain from a sale of intellectual property.
RECONCILIATION FROM GAAP NET SALES GROWTH TO NON-GAAP ORGANIC NET SALES GROWTH
Three Months Ended
September 30, 2026
Nine Months Ended
September 30, 2026
Net sales growth
33.7
%
32.7
%
Impact of Copra acquisition
16.0
%
6.0
%
Organic net sales growth
17.8
%
26.7
%
SUPPLEMENTAL INFORMATION
NET SALES
Three Months Ended September 30,
Nine Months Ended September 30,
(in thousands)
2026
2025
2026
2025
Americas segment
Vita Coco Coconut Water
$
143,276
$
132,438
$
399,231
$
339,006
Private Label
46,495
14,360
97,795
50,242
Other
8,786
4,926
22,162
17,037
Subtotal
$
198,557
$
151,724
$
519,188
$
406,285
International segment
Vita Coco Coconut Water
$
34,363
$
21,939
$
88,645
$
54,998
Private Label
10,297
8,137
30,462
19,118
Other
608
513
1,449
1,592
Subtotal
$
45,268
$
30,589
$
120,556
$
75,708
Total net sales
$
243,825
$
182,313
$
639,744
$
481,993
COST OF GOODS SOLD & GROSS PROFIT
Three Months Ended September 30,
Nine Months Ended September 30,
(in thousands)
2026
2025
2026
2025
Cost of goods sold
Americas segment
$
122,824
$
93,859
$
293,240
$
255,062
International segment
28,324
19,786
76,702
48,913
Total cost of goods sold
$
151,148
$
113,645
$
369,942
$
303,975
Gross profit
Americas segment
$
75,732
$
57,866
$
225,948
$
151,224
International segment
16,945
10,802
43,854
26,794
Total gross profit
$
92,677
$
68,668
$
269,802
$
178,018
Gross margin
Americas segment
38.1
%
38.1
%
43.5
%
37.2
%
International segment
37.4
%
35.3
%
36.4
%
35.4
%
Consolidated
38.0
%
37.7
%
42.2
%
36.9
%
VOLUME (CE)
Percentage Change -
Three Months Ended September 30, 2026
vs.
2025
Americas segment
International segment
Total
Vita Coco Coconut Water
8.5
%
50.5
%
15.8
%
Private Label
109.9
%
23.1
%
76.7
%
Other
34.9
%
108.7
%
35.8
%
Subtotal
22.5
%
42.1
%
26.5
%
Percentage Change -
Nine Months Ended September 30, 2026
vs.
2025
Americas segment
International segment
Total
Vita Coco Coconut Water
13.2
%
52.5
%
19.7
%
Private Label
63.4
%
48.8
%
58.9
%
Other
16.6
%
(14.2
)%
15.8
%
Subtotal
21.2
%
51.0
%
26.8
%
Note: A CE is a standard volume measure used by management which is defined as a case of 12 bottles of 330ml liquid beverages or the same liter volume of oil. We may have immaterial sales of raw materials at times that are treated as zero CEs for the purposes of these calculations.
Net Sales Increased 34%, Driven by Vita Coco Coconut Water Growth of 15%; Organic Net Sales Growth
1
of 18%
Net Income Increased $11 million to $35 million and Non-GAAP Adjusted EBITDA² Increased $21 million to $53 million
Raises Fiscal Year 2026 Guidance for Net Sales to Between
$810
Million and
$820
Million and Non-GAAP Adjusted EBITDA²
to between
$170
million and
$175
million
NEW YORK, Oct. 22, 2026 (GLOBE NEWSWIRE) -- The Vita Coco Company, Inc. (NASDAQ:COCO) (“Vita Coco” or “the Company”), a leading high-growth platform of better-for-you beverage brands, today announced financial results for the third quarter ended September 30, 2026.
Third Quarter and Year-to-Date 2026 Highlights Compared to Prior Year Period
Net sales were $244 million, an increase of $62 million, or 34%, in the third quarter
,
and $640 million year-to-date, an increase of $158 million, or 33%.
Organic net sales growth
1
was 18% in the third quarter and 27% year-to-date.
Vita Coco
Coconut Water net sales grew 15% in the third quarter and 24% year-to-date.
Private Label net sales grew 152% in the third quarter and 85% year-to-date, with the third quarter benefiting from the contribution of Copra, a leading producer of super premium Thai Nam Hom coconut water that was acquired in July 2026.
Gross profit was $93 million in the third quarter, an increase of $24 million, and $270 million year-to-date, an increase of $92 million.
Gross margin was 38% of net sales in the third quarter consistent with prior year, and was 42% of net sales year-to-date compared to 37%, with tariff refunds delivering a 240 basis point benefit to gross margin year-to-date.
Net income was $35 million in the third quarter, compared to $24 million, an increase of $11 million, and $115 million year-to-date, compared to $66 million, an increase of $49 million.
Net income per diluted share was $0.58 in the third quarter, compared to $0.40, and $1.89 per diluted share year-to-date, compared to $1.10.
Non-GAAP Adjusted EBITDA² was $53 million in the third quarter, compared to $32 million, an increase of $21 million. Non-GAAP Adjusted EBITDA
2
was $159 million year-to-date, compared to $84 million, an increase of $75 million.
Michael Kirban, the Company's Co-Founder and Executive Chairman, stated, “The growth of the coconut water category maintained through the fall, and remains one of the fastest growing beverage categories in our major markets. I am particularly pleased by the strong growth in Europe as we develop the category in key markets, and the continued growth in America, driven by increases in both household penetration and in average consumption per household. This quarter, we were pleased to welcome the Copra team to our family and to start executing our joint plans, which we believe will allow us to compete successfully in the super premium segment. With the investments we are making in our supply chain, and our strong brand performance, I am confident in our plans to maintain our growth into 2027, and our category leadership well into the future.”
Martin Roper, the Company’s Chief Executive Officer, said, “Our strong third quarter net sales growth was driven by robust branded retail growth in all our major markets, and by strong growth in private label shipments, reflecting healthy category growth and the addition of Copra's super premium products. Excluding the impact of Copra, the underlying 18% organic net sales growth of our business remained very strong, exceeding our expectations. Consumer demand is very healthy, and we are therefore raising our full year Net Sales and Adjusted EBITDA guidance.”
Third Quarter 2026 Consolidated Results
Net sales increased $62 million, or 34%, to $244 million for the third quarter ended September 30, 2026, compared to $182 million in the prior year period. The increase in net sales was driven by case equivalent (“CE”) volume gains of 16% for
Vita Coco
Coconut Water and 77% for Private Label. Organic net sales growth
1
, which is net sales growth excluding the impact of Copra, was 18% for the quarter. Copra net sales primarily impacted Private Label, with Copra branded coconut water and commodity net sales recognized in Other.
Gross profit increased to $93 million, from $69 million in the prior year period driven by higher sales volume, the addition of Copra, and minimal tariffs compared to the prior year period, partially offset by higher domestic logistics costs. Gross margin was 38%, in line with the prior year period, benefitting from minimal tariffs compared to the prior year period, offset by higher domestic logistics costs, and the dilutive impact of Copra.
Selling, general and administrative (“SG&A”) expenses were $47 million, compared to $41 million in the prior year period. The increase was primarily driven by costs related to the acquisition of Copra, amortization expense associated with intangible assets acquired in the Copra acquisition, higher people-related costs reflecting increased headcount and stock-based compensation, as well as higher sales related expenses.
Net income was $35 million, or $0.58 per diluted share, compared to net income of $24 million, or $0.40 per diluted share, in the prior year period. Net income benefited from higher gross profit, partially offset by higher SG&A spending and increased income tax expense.
Non-GAAP Adjusted EBITDA
2
was $53 million, compared to $32 million in the prior year due to the increased gross profit partially offset by higher SG&A expenses.
Balance Sheet
As of September 30, 2026, the Company's financial position remained strong with no debt and $152 million in cash and cash equivalents. Cash decreased $45 million from the beginning of the year, and $127 million from end of the second quarter due to net cash used for the acquisition of Copra of $139 million. Our inventory was $111 million, flat to December 31, 2025, with the inclusion of Copra inventory offsetting the inventory draw down from strong year-to-date shipments. Accounts receivable increased to $129 million from $82 million as of prior year end due to strong quarterly sales and the inclusion of Copra.
As of September 30, 2026, the Company had repurchased approximately $86 million of its common stock under its share repurchase program and had $19 million remaining under the existing authorization. During the nine months ended September 30, 2026, the Company repurchased $62 million of its common stock. As of October 22, 2026, the Company has repurchased $94 million of its common stock, and had $11 million remaining of the $105 million authorized amount under the repurchase program.
Fiscal Year 2026 Full Year Outlook³
The Company is increasing its full year 2026 guidance, as follows:
Net sales expected to be between $810 million and $820 million, driven by low 20s percent growth of Vita Coco Coconut Water, strong Private Label trends and the addition of Copra. (Prior guidance was between $790 million and $805 million, which included the benefit of Copra).
Gross margin expected to be approximately 40% with benefit relative to prior year from lower tariffs, tariff refunds, and higher pricing partially offset by increased ocean freight, product and other transportation costs, alongside adverse product mix, primarily due to the impact of Copra's private label business and strong private label trends. (No change from prior guidance). Fourth quarter gross margin expected to be approximately 33% due to increases in cost of goods and no offsetting price actions expected until early 2027.
Expect to deliver SG&A leverage of approximately 1.5 percentage points of net sales vs. 2025. (Prior guidance was one percentage point).
Adjusted EBITDA
²
expected to be in the range of $170 million to $175 million. (Prior guidance was between $154 million and $161 million).
Uncertainty and instability in the current operating environment, geopolitical landscape, and global economies, including the military conflict in Iran and related impacts, changes in tariff rates, natural disasters, associated potential competitive pricing actions, and our own price elasticity could affect this outlook and our future results.
Footnotes
(1)
Organic net sales growth is a supplemental measure of net sales performance that excludes the impact of net sales attributable to the Copra acquisition as set forth in the U.S. GAAP to non-GAAP reconciliation table below.
(2)
Adjusted EBITDA represents earnings before interest, taxes, depreciation, and amortization as adjusted for certain items as set forth in the reconciliation table of U.S. GAAP to non-GAAP information and is a measure calculated and presented on the basis of methodologies other than in accordance with GAAP. Please refer to the Non-GAAP Financial Measures herein for further discussion and reconciliation of this measure to GAAP measures.
(3)
GAAP Net income 2026 outlook is not provided due to the inherent difficulty in quantifying certain amounts due to a variety of factors including the unpredictability in the movement in foreign currency rates, as well as future charges or reversals outside of the normal course of business.
Conference Call and Webcast Details
To participate in the live earnings call and question and answer session, please register at
https://register-conf.media-server.com/register/BIb7dfca7ed24e41c7a1cd98a3f2cfb4e0
and dial-in information will be provided directly to you. The live audio webcast will be accessible in the “Events” section of the Company’s Investor Relations website at
https://investors.thevitacococompany.com
. An archived replay of the webcast will be available shortly after the live event has concluded.
About The Vita Coco Company
The Vita Coco Company is a family of brands on a mission to reimagine what’s possible when brands deliver healthy, nutritious
,
and great tasting products that are better for consumers and better for the world. This includes its flagship coconut water brand Vita Coco, and Copra, a super-premium brand that specializes in Thai Nam Hom coconut water. The Company was co-founded in 2004 by Michael Kirban and Ira Liran and is a public benefit corporation and Certified B Corporation. Vita Coco, the principal brand within the Company’s portfolio, is the leading coconut water brand in the U.S. With electrolytes and nutrients, coconut water has become a top beverage choice among consumers after a workout, in smoothies, as a cocktail mixer, after a night out and more.
Contacts
Investor Relations:
ICR, Inc.
investors@thevitacococompany.com
Non-GAAP Financial Measures
In addition to disclosing results determined in accordance with U.S. GAAP, the Company also discloses certain non-GAAP results of operations, including, but not limited to, Adjusted EBITDA, and organic net sales growth, which include certain adjustments or exclude certain charges and gains that are described in the reconciliation table of U.S. GAAP to non-GAAP information provided at the end of this release. These non-GAAP measures are a key metric used by management and our board of directors to assess our financial performance across reporting periods on a consistent basis by excluding items that we do not believe are indicative of our core operating performance and because we believe it is useful for investors to see the measures that management uses to evaluate the Company. In addition, we believe the presentation of these measures is useful to investors for period-to-period comparisons of results as the items described below in the reconciliation tables do not reflect ongoing operating performance.
These measures are not in accordance with, or an alternative to, U.S. GAAP, and may be different from non-GAAP measures used by other companies. In addition, other companies, including companies in our industry, may calculate such measures differently, which reduces their usefulness as a comparative measure. Investors should not rely on any single financial measure when evaluating our business. This information should be considered as supplemental in nature and is not meant as a substitute for our operating results in accordance with U.S. GAAP. We recommend investors review the U.S. GAAP financial measures included in this earnings release. When viewed in conjunction with our U.S. GAAP results and the accompanying reconciliations, we believe these non-GAAP measures provide greater transparency and a more complete understanding of factors affecting our business than U.S. GAAP measures alone.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, but not limited to, statements regarding our future financial and operating performance, including our GAAP and non-GAAP guidance, our strategy, projected costs, tariffs, prospects, expectations, plans, objectives of management, supply chain predictions, customer and supplier relationships, expected impact of acquisitions, and expected net sales and category share growth.
The forward-looking statements in this release are only predictions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Forward-looking statements involve a number of risks, uncertainties or other factors beyond the Company’s control. These factors include, but are not limited to, those discussed under the caption “Risk Factors” in our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and our other filings with the U.S. Securities and Exchange Commission (“SEC”) as such factors may be updated from time to time and which are accessible on the SEC’s website at www.sec.gov and the Investor Relations page of our website at https://investors.thevitacococompany.com. Any forward-looking statements contained in this press release speak only as of the date hereof and accordingly undue reliance should not be placed on such statements. We disclaim any obligation or undertaking to update or revise any forward-looking statements contained in this press release, whether as a result of new information, future events or otherwise, other than to the extent required by applicable law.
Website Disclosure
We intend to use our websites, vitacoco.com and investors.thevitacococompany.com, as a means for disclosing material non-public information and for complying with the SEC's Regulation FD and other disclosure obligations.
THE VITA COCO COMPANY, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(Amounts in thousands, except share data)
September 30,
2026
December 31,
2025
Assets
Current assets:
Cash and cash equivalents
$
151,995
$
196,873
Accounts receivable, net of allowance of $3,282 at September 30, 2026, and $2,660 at December 31, 2025
128,724
81,514
Inventory
111,296
111,468
Supplier advances, current
339
693
Derivative assets
1,794
732
Prepaid expenses and other current assets
39,536
30,160
Total current assets
433,684
421,440
Property and equipment, net
24,441
9,298
Goodwill
110,175
7,791
Intangible assets, net
107,116
—
Supplier advances, long-term
1,593
1,860
Deferred tax assets, net
6,627
6,623
Right-of-use assets, net
10,337
11,592
Other assets
2,169
2,714
Total assets
$
696,142
$
461,318
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable
$
46,389
$
25,464
Accrued expenses and other current liabilities
126,632
89,461
Derivative liabilities
2,059
1,507
Total current liabilities
175,080
116,432
Deferred tax liability
24,875
160
Operating lease liability, long-term
12,119
13,087
Seller's earn-out
55,100
—
Other long-term liabilities
240
97
Total liabilities
$
267,414
$
129,776
Stockholders’ equity:
Common stock, $0.01 par value; 500,000,000 shares authorized; 65,396,253 and 64,186,549 shares issued at September 30, 2026 and December 31, 2025, respectively; 57,202,356 and 57,082,173 shares outstanding at September 30, 2026 and December 31, 2025, respectively.
654
642
Additional paid-in capital
231,578
185,400
Retained earnings
342,956
228,014
Accumulated other comprehensive gain (loss)
(1,050
)
486
Treasury stock, 8,193,897 shares at cost as of September 30, 2026, and 7,104,376 as of December 31, 2025.
(145,410
)
(83,000
)
Total stockholders’ equity
428,728
331,542
Total liabilities and stockholders’ equity
$
696,142
$
461,318
THE VITA COCO COMPANY, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Amounts in thousands, except for share and per share data)
Three Months Ended September 30,
Nine Months Ended September 30,
2026
2025
2026
2025
Net sales
$
243,825
$
182,313
$
639,744
$
481,993
Cost of goods sold
151,148
113,645
369,942
303,975
Gross profit
92,677
68,668
269,802
178,018
Operating expenses
Selling, general and administrative
47,226
40,745
127,629
105,680
Income from operations
45,451
27,923
142,173
72,338
Other income (expense)
Unrealized (loss) gain on derivative instruments
(2,083
)
2,391
511
6,275
Foreign currency loss
(887
)
(1,411
)
(2,432
)
(349
)
Interest income, net
1,231
1,776
5,252
4,794
Other (expense) income, net
(84
)
—
(77
)
155
Total other (expense) income
(1,823
)
2,756
3,254
10,875
Income before income taxes
43,628
30,679
145,427
83,213
Income tax expense
8,611
6,676
30,485
17,420
Net income
$
35,017
$
24,003
$
114,942
$
65,793
Net income attributable to The Vita Coco Company, Inc. per common share
Basic
$
0.61
$
0.42
$
2.01
$
1.16
Diluted
$
0.58
$
0.40
$
1.89
$
1.10
Weighted-average number of common shares outstanding
Basic
57,453,252
56,850,812
57,274,270
56,879,627
Diluted
60,831,632
59,878,602
60,786,462
59,832,067
THE VITA COCO COMPANY, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Amounts in thousands)
Nine Months Ended September 30,
2026
2025
Cash flows from operating activities:
Net income
$
114,942
$
65,793
Adjustments required to reconcile net income to cash flows from operating activities:
Depreciation and amortization
2,458
636
Amortization of debt issuance cost
14
11
Increase of provision for credit losses
187
1,300
Unrealized (gain) on derivative instruments
(511
)
(6,275
)
Stock-based compensation
11,338
8,123
Impairment loss on Runa assets
—
185
Noncash lease expense
1,242
1,052
Changes in operating assets and liabilities:
Accounts receivable
(42,801
)
(39,706
)
Inventory
33,259
(302
)
Prepaid expenses, net supplier advances, and other assets
(7,236
)
345
Accounts payable, accrued expenses, and other liabilities
39,050
19,907
Net cash provided by operating activities
151,942
51,069
Cash flows from investing activities:
Cash paid for property and equipment
(803
)
(4,921
)
Acquisition of Copra Inc., net of $8,340 cash acquired
(139,253
)
—
Net cash used in investing activities
(140,056
)
(4,921
)
Cash flows from financing activities:
Proceeds from exercise of stock awards
6,131
2,281
Cash paid on notes payable
(3
)
(8
)
Cash paid to acquire treasury stock
(62,410
)
(10,204
)
Net cash used in financing activities
(56,282
)
(7,931
)
Effects of exchange rate changes on cash and cash equivalents
(475
)
833
Net (decrease) increase in cash and cash equivalents
(44,871
)
39,050
Cash, cash equivalents and restricted cash at beginning of the period (1)
198,154
165,933
Cash, cash equivalents and restricted cash at end of the period (1)
$
153,283
204,983
1
Includes $1,281 and $1,264 of restricted cash as of December 31, 2025 and 2024, respectively. Includes $1,288 and $1,278 of restricted cash as of September 30, 2026 and 2025, respectively, reported in other current assets on the condensed consolidated balance sheet.
During the nine months ended September 30, 2026, the Company issued common stock with a fair value of $35,000 and recognized contingent consideration with a fair value of $55,100 in connection with the acquisition of Copra. These transactions are reflected as noncash investing and financing activities.
RECONCILIATION FROM GAAP NET INCOME TO NON-GAAP ADJUSTED EBITDA
Three Months Ended September 30,
Nine Months Ended September 30,
2026
2025
2026
2025
(in thousands)
(in thousands)
Net income
35,017
24,003
$
114,942
$
65,793
Depreciation and amortization
1,493
228
2,458
636
Interest income, net
(1,231
)
(1,776
)
(5,252
)
(4,794
)
Income tax expense
8,611
6,676
30,485
17,420
EBITDA
$
43,890
$
29,131
$
142,633
$
79,055
Stock-based compensation (a)
3,122
2,975
11,338
8,123
Unrealized loss (gain) on derivative instruments (b)
2,083
(2,391
)
(511
)
(6,275
)
Foreign currency loss (b)
887
1,411
2,432
349
Acquisition-related costs (c)
3,174
—
3,174
—
Other adjustments (d)
—
1,264
—
2,886
Adjusted EBITDA
$
53,156
$
32,390
$
159,066
$
84,138
(a)
Non-cash charges related to stock-based compensation, which vary from period to period depending on volume and vesting timing of awards and forfeitures. We adjusted for these charges to facilitate comparison from period to period.
(b)
Unrealized gains or losses on derivative instruments and foreign currency gains or losses are not considered in our evaluation of our ongoing performance.
(c)
Acquisition-related costs represent transaction, advisory, legal, accounting, valuation, and other professional fees incurred in connection with the acquisition of Copra.
(d)
The three and nine months ended September 30, 2025 included $0.6 million and $1.8 million, respectively, related to a one-time incentive program established in 2023 and measured based on full-year 2025 performance, and $0.4 million and $1.1 million, respectively, of overlapping rent expense associated with our new New York City office, and $0.2 million of impairment loss related to the sale of Runa. The three months ended September 30, 2025 also includes $0.1 million of provision for credit losses related to the partially recovered prepaid inventory from a supplier recorded in the first half of 2025 (refer to the Form 10-K and the Form 10-Q for the quarterly period ended June 30, 2025 for further details). The nine month period was partially offset by $0.1 million of partial recoveries of prepaid inventory from a supplier (refer to the Form 10-K for further details) and a $0.2 million gain from a sale of intellectual property.
RECONCILIATION FROM GAAP NET SALES GROWTH TO NON-GAAP ORGANIC NET SALES GROWTH
Three Months Ended
September 30, 2026
Nine Months Ended
September 30, 2026
Net sales growth
33.7
%
32.7
%
Impact of Copra acquisition
16.0
%
6.0
%
Organic net sales growth
17.8
%
26.7
%
SUPPLEMENTAL INFORMATION
NET SALES
Three Months Ended September 30,
Nine Months Ended September 30,
(in thousands)
2026
2025
2026
2025
Americas segment
Vita Coco Coconut Water
$
143,276
$
132,438
$
399,231
$
339,006
Private Label
46,495
14,360
97,795
50,242
Other
8,786
4,926
22,162
17,037
Subtotal
$
198,557
$
151,724
$
519,188
$
406,285
International segment
Vita Coco Coconut Water
$
34,363
$
21,939
$
88,645
$
54,998
Private Label
10,297
8,137
30,462
19,118
Other
608
513
1,449
1,592
Subtotal
$
45,268
$
30,589
$
120,556
$
75,708
Total net sales
$
243,825
$
182,313
$
639,744
$
481,993
COST OF GOODS SOLD & GROSS PROFIT
Three Months Ended September 30,
Nine Months Ended September 30,
(in thousands)
2026
2025
2026
2025
Cost of goods sold
Americas segment
$
122,824
$
93,859
$
293,240
$
255,062
International segment
28,324
19,786
76,702
48,913
Total cost of goods sold
$
151,148
$
113,645
$
369,942
$
303,975
Gross profit
Americas segment
$
75,732
$
57,866
$
225,948
$
151,224
International segment
16,945
10,802
43,854
26,794
Total gross profit
$
92,677
$
68,668
$
269,802
$
178,018
Gross margin
Americas segment
38.1
%
38.1
%
43.5
%
37.2
%
International segment
37.4
%
35.3
%
36.4
%
35.4
%
Consolidated
38.0
%
37.7
%
42.2
%
36.9
%
VOLUME (CE)
Percentage Change -
Three Months Ended September 30, 2026
vs.
2025
Americas segment
International segment
Total
Vita Coco Coconut Water
8.5
%
50.5
%
15.8
%
Private Label
109.9
%
23.1
%
76.7
%
Other
34.9
%
108.7
%
35.8
%
Subtotal
22.5
%
42.1
%
26.5
%
Percentage Change -
Nine Months Ended September 30, 2026
vs.
2025
Americas segment
International segment
Total
Vita Coco Coconut Water
13.2
%
52.5
%
19.7
%
Private Label
63.4
%
48.8
%
58.9
%
Other
16.6
%
(14.2
)%
15.8
%
Subtotal
21.2
%
51.0
%
26.8
%
Note: A CE is a standard volume measure used by management which is defined as a case of 12 bottles of 330ml liquid beverages or the same liter volume of oil. We may have immaterial sales of raw materials at times that are treated as zero CEs for the purposes of these calculations.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
86d563caeb· 2026-10-22 19:09 · doubao / doubao-seed-evolving-latest-version · 策略包658c0c1e2ba5当前